Rubius Therapeutics, Inc. (RUBY)
| Market Cap | 826.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -171.66M |
| Shares Out | 80.78M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $10.21 |
| Previous Close | $10.00 |
| Change ($) | 0.21 |
| Change (%) | 2.10% |
| Day's Open | 10.07 |
| Day's Range | 10.05 - 10.66 |
| Day's Volume | 706,410 |
| 52-Week Range | 3.74 - 10.66 |
Rubius has an interesting science hypothesis, however it failed a first proof of concept trial. It is now running its next one. They have adequate cash for the time being.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial
RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and E...
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to creat...
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulatio...
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...
These biotechs have a long road ahead, but they just might deliver massive growth.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...
Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory RTX-321 May Induce Epitope Spreading and Long-Term Tumor Memory
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to crea...
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to crea...
Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
Rubius Therapeutics' (RUBY) CEO Pablo Cagnoni on Q4 2019 Results - Earnings Call Transcript
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cre...
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to cr...
About RUBY
Rubius Therapeutics focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Industry Biotechnology | IPO Date Jul 18, 2018 |
| CEO Pablo Cagnoni | Employees 197 |
| Stock Exchange NASDAQ | Ticker Symbol RUBY |
Analyst Forecasts
According to 7 analysts, the average rating for RUBY stock is "Buy." The 12-month stock price forecast is 10.29, which is an increase of 0.78% from the latest price.